ABIVAX Société Anonyme (NASDAQ:ABVX) Earns “Market Outperform” Rating from JMP Securities

ABIVAX Société Anonyme (NASDAQ:ABVX)‘s stock had its “market outperform” rating restated by JMP Securities in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $33.00 price objective on the stock. JMP Securities’ price objective would indicate a potential upside of 402.28% from the stock’s previous close.

Separately, Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $38.67.

ABIVAX Société Anonyme Stock Down 1.6 %

Shares of ABIVAX Société Anonyme stock traded down $0.11 during trading hours on Friday, reaching $6.57. The company’s stock had a trading volume of 32,153 shares, compared to its average volume of 113,469. The stock’s fifty day simple moving average is $8.46 and its two-hundred day simple moving average is $10.51. ABIVAX Société Anonyme has a one year low of $6.53 and a one year high of $17.02.

Institutional Trading of ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently modified their holdings of ABVX. GAMMA Investing LLC purchased a new position in ABIVAX Société Anonyme in the fourth quarter worth $29,000. BNP Paribas Financial Markets boosted its holdings in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the period. Walleye Capital LLC lifted its holdings in ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares in the last quarter. abrdn plc boosted its stake in ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.